Targeting Cellular Signalling Pathways in Lung Diseases, 1st ed. 2021

The book comprehensively reviews and provides detailed insight into the cellular and molecular signalling mechanisms involved in pathophysiology of various respiratory diseases, towards developing effective therapeutic strategies in the management and treatment of lung disease. It also covers promising advances in the field of therapeutics that could lead to novel clinical therapies capable of preventing or reversing the disease features including novel strategies for targeting chronic lung diseases using advanced drug delivery systems. Importantly, the book examines the significance and relevance of the plant extracts and their constituents with therapeutic efficiencies against lung diseases. As such, the book offers a blend of translational, biological, chemical, and drug delivery aspects relevant to respiratory diseases, thus, offering a valuable resource for pulmonologists and translational researchers working in the field of pulmonary biology and respiratory medicine.

Chapter 1. Introduction to Lung Diseases.- Chapter 2. Targeting molecular and cellular mechanisms in asthma.-Chapter 3. Various cellular and molecular axis involved in the pathogenesis of asthma.- Chapter 4. Targeting molecular and cellular mechanisms in steroid resistant asthma.- Chapter 5. Targeting molecular and cellular mechanisms in chronic obstructive pulmonary disease.- Chapter 6. Probing the cellular and molecular mechanisms underlying in the pathogenesis of Chronic Obstructive Pulmonary Disease (COPD).- Chapter 7. Chronic obstructive pulmonary disease: Molecular basis of pathogenesis and targeted therapeutic approaches.- Chapter 8. Exploring the ‘dormancy-activation switch’ in the tumour microenvironment for metastatic lung cancer: The possible role of microRNA.- Chapter 9. Therapeutic strategies targeting signalling pathways in lung cancer.- Chapter 10. Modulation of signalling pathways by immunotherapeutics in lung cancer.- Chapter 11. Underpinning the Cellular and Molecular Mechanisms with Nanotheronstics for Lung Cancer.- Chapter 12. Targeting molecular and cellular mechanisms in Idiopathic Pulmonary Fibrosis.-Chapter 13. A refined approach to target the molecular and cellular mechanisms in pulmonary fibrosis.-Chapter 14. Targeting molecular and cellular mechanisms in tuberculosis.- Chapter 15. Cellular and Molecular Mechanisms of Repurposed antidiabetic drug as adjunctive treatment for tuberculosis.- Chapter 16. Targeting host and bacterial signaling pathways in tuberculosis: An effective strategy for the development of novel anti-tubercular therapies.- Chapter 17. Targeting molecular and cellular mechanisms in pulmonary hypertension.- Chapter 18. Targeting molecular and cellular mechanisms in pulmonary arterial hypertension.- Chapter 19. Potential cellular targets associated with the signaling and therapeutics of the pulmonary hypertension.- Chapter 20. Targeting molecular and cellular mechanisms in influenza A virus infections.- Chapter 21. Understanding the Biology of Non-typeable Haemophilus influenzae in Chronic Obstructive Pulmonary Disease through the Lens of Genomics.- Chapter 22. Targeting molecular and cellular mechanisms in rhinovirus infection.- Chapter 23. Targeting molecular and cellular mechanisms in respiratory syncytial virus (RSV) infection.- Chapter 24. Targeting molecular and cellular mechanisms SARS-CoV2 novel corona (COVID-19) virus infection.- Chapter 25. Underpinning the rudimentary mechanisms involved in the pathogenesis of SARS-CoV2 (COVID-19) in human lung cells.- Chapter 26. Targeting molecular and cellular mechanisms in SARS-CoV2 novel corona (COVID-19) virus infection.- Chapter 27. Special features of human lung ACE2 sensitivity to SARS CoV-2 spike glycoprotein.- Chapter 28. Implications of Phosphoinositide 3-kinase (PI3K) Signalling in cellular and molecular mechanisms of respiratory diseases.- Chapter 29. The role of the cholinergic system in lung diseases.- Chapter 30. The Nrf2-Keap1 signaling pathway in lung cancer.- Chapter 31. Role of Toll like receptor (LTR) in molecular and cellular mechanism of respiratory diseases.- Chapter 32. Biomarkers of Oxidative Stress.- Chapter 33. Targeting chronic lung diseases using advanced drug delivery systems.- Chapter 34. Plant based chemical moieties targeting cellular signalling pathways in chronic lung diseases.- Chapter 35. Role of phytoconstituents in targeting cytokines for managing pathophysiology of lung diseases.- Chapter 36. Targeting Cellular Signaling Pathways in Lung Cancer and Role of Phytochemicals as Novel Therapeutic Approach.- Chapter 37. Natural compounds targeting major signalling pathways in lung cancer.- Chapter 38. Drug delivery in respiratory diseases: Current opportunities,  Molecular and cellular mechanism, and Future challenges.- Chapter 39. Future prospects and challenges in targeting cellular and molecular mechanisms in respiratory diseases.

Kamal Dua is a Senior Lecturer in the Discipline of Pharmacy at the Graduate School of Health, University of Technology Sydney (UTS), Australia. He has research experience of over 12 years in the field of drug delivery systems targeting inflammatory diseases. Dr. Dua is also a Node Leader of Drug Delivery Research in the Centre for Inflammation at Centenary Institute/UTS, where the targets identified from the research projects are pursued to develop novel formulations as the first step towards translation into clinics. Dr. Dua researches in two complementary areas; drug delivery and immunology, specifically addressing how these disciplines can advance one another helping the community to live longer and healthier. This is evidenced by his extensive publication record in reputed journals. Dr. Dua’s research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as interleukins and microRNAs and developing new and effective drug delivery formulations for the management of chronic airway diseases. He has published more than 80 research articles in peer-reviewed international journals and authored or co-authored four books. He is an active member of many national and international professional societies. 

Raimar Löbenberg holds a BS in Pharmacy from the Johannes Gutenberg-University in Mainz, Germany, and received his PhD in Pharmaceutics from the Johann Wolfgang Goethe-University. His research interests are in Biopharmaceutics and inhalable nanoparticles to treat lung diseases. He is a founder and Director of the Drug Development and Innovation Centre at the University of Alberta. He was president of the Canadian Society for Pharmaceutical Sciences 2014–2015 and a member of the United States Pharmacopeia Dietary Supplement Expert Committee. He is a Vice-chair of the Specialty Committee of Traditional Chinese Medicine in Pharmaceutics of the World Foundation of Chinese Medicine Science. He is a member of the Heal

Presents recent perspectives and challenges of treating lung diseases

Examines the molecular and cellular mechanisms involved in the pathogenesis of lung diseases

Exploring novel and effective approaches for the prevention and treatment of respiratory diseases

Review drug delivery systems and phytoconstituents for targeting cellular and molecular mechanisms in respiratory diseases